Gene Polymorphisms Influence Exenatide Therapeutic Responses in Chinese Type 2 Diabetes Patients

Type 2 diabetes mellitus (T2DM) is a prevalent chronic metabolic disorder with increasing global incidence, imposing significant healthcare burdens. Effective long-term management strategies are crucial for improving patient outcomes and promoting disease control. While GLP-1 receptor agonists (GLP-1 RAs) like exenatide offer significant benefits in glycemic control and weight management, individual patient responses vary. Understanding the genetic factors, such as polymorphisms in genes like GLP-1R, NOS1AP, KCNQ1, TCF7L2, and WSF1, that influence both T2DM susceptibility and therapeutic efficacy could pave the way for personalized medicine approaches.

This retrospective cohort study analyzed data from Chinese patients with T2DM who received exenatide twice daily as part of their standard diabetes care. Patients were treated for a minimum duration of 12 months. The primary objective was to investigate the influence of various T2DM susceptibility gene polymorphisms, including those in NOS1AP, KCNQ1, TCF7L2, WSF1, and GLP-1R, on the efficacy of GLP-1 RAs, specifically exenatide. The study aimed to identify variables capable of predicting GLP-1 RA efficacy and to evaluate the relative weight of these variables.

The abstract for this retrospective cohort study primarily outlined its objectives, focusing on the investigation of gene polymorphism influence on GLP-1 RA efficacy. No specific findings, statistical data, or quantitative results from the study were presented within the abstract itself. The abstract stated the aim was to identify variables that can predict the efficacy of GLP-1 RA and to evaluate the weight of these variables, but did not report the outcomes of this investigation.